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Abstract 
Previous observational studies have found a relationship between vitamin D deficiency and non-
alcoholic fatty liver disease (NAFLD). However, this type of study could not show the causal 
relationship between these two conditions. Therefore, we systematically and critically reviewed 
the available clinical trials to elucidate such relationship. We searched databases such as 
Medline, Scopus and Cochrane to identify the clinical trials that assessed the effects of vitamin D 
supplementation in adults with NAFLD. The outcome variables of interest were indicators of 
hepatic steatosis, liver enzymes, insulin resistance, inflammation and oxidative stress. A total of 
6 studies were included in the qualitative analysis. Only in two studies the grade of hepatic 
steatosis decreased significantly after vitamin D supplementation. The changes in insulin 
resistance parameters were reported significant only in one. Of the 3 included studies that 
measured biomarkers of inflammation and oxidative stress, one revealed a significant decrease in 
these biomarkers after vitamin D supplementation. Findings from current review study provided 
new insight into the factors that could affect the therapeutic role of vitamin D in NAFLD. 
Factors such as gender differences, baseline serum status of vitamin D, co-supplementation with 
calcium and gene polymorphism should be considered when designing future clinical trials. 
Keywords: vitamin D, supplementation, Non-alcoholic fatty liver disease, clinical trials, 
systematic review 
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1. INTRODUCTION 
Recent evidence indicates that vitamin D may exert immunomodulatory, anti inflammatory and 
antioxidant effect in both animal models and human (Zhu et al., 2017; Dankers et al., 2016; 
Eliades and Spyrou, 2015). What distinguishes vitamin D from other vitamins is its function as a 
hormone in the body. The biological roles of vitamin D are mediated via a nuclear vitamin D 
receptor (VDR) (Picciano, 2010). Following recent advances in cellular and molecular methods, 
it has been shown that VDR is expressed in various tissues of the human body (Altieri et al., 
2017). Vitamin D only in its active form is able to bind to VDR (Picciano, 2010). The active 
form of vitamin D is produced in two steps in the body. First, vitamin D, originated from dietary 
sources or endogenously synthesized in the body following ultra violet radiation, undergoes 25-
hydroxylation in the liver. Then, the enzyme1-α hydroxylase in the kidneys converts 25-
hydroxyvitamin D (25 (OH) D) to the active form 1,25-dihydroxyvitamin D [1,25(OH)2D] 
(Holick, 2007; Prosser and Jones, 2004). Interestingly, it has been found that in addition to the 
kidneys, the cells of other tissues such as pancreas β cells, macrophages and immune cells also 
produce 1-α hydroxylase, resulting in the local production of 1,25(OH)2D in corresponding 
tissues (Dankers et al., 2016; Takiishi et al., 2012). This evidence would support the proposed 
roles of vitamin D in various diseases, such as different types of infectious and autoimmune 
diseases as well as cancers, diabetes and metabolic syndrome (Adams and Hewison, 2010). 
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The results of some previous studies showed a relationship between vitamin D deficiency (VDD) 
and metabolic syndrome‟s components such as insulin resistance and dyslipidemia (Challoumas, 
2014; Hyppönen et al., 2008; Pittas and Dawson-Hughes, 2010). This relationship proposed a 
new hypothesis that vitamin D deficiency might be associated with non-alcoholic fatty liver 
disease (NAFLD) as a hepatic feature of metabolic syndrome. NAFLD occurs when triglyceride 
is accumulated in hepatic cells due to metabolic causes other than excessive alcohol use(Clark et 
al., 2002).  The spectrum of disease includes simple steatosis, non-alcoholic steatohepatitis 
(NASH) and liver cirrhosis (Farrell and Larter, 2006). Evidence from previous cellular and 
experimental studies has suggested various mechanisms by which vitamin D deficiency could be 
connected to NAFLD pathogenesis. Vitamin D might improve insulin secretion and function 
(Maestro et al., 2003; Maestro et al., 2002). Additionally, extensive VDR expression in non-
parenchymal liver cells like macrophages, Kuppfer cells, and hepatic stellate cells (HSC) 
represents this fact that vitamin D could exert anti-inflammatory, anti fibrotic and anti-
proliferative properties (Zúñiga et al., 2011; Geier, 2011). As a result, vitamin D might prevent 
NAFLD progression from simple steatosis to more advanced form of steatohepatitis and fibrosis, 
independently from other risk factors such as BMI (Eliades and Spyrou, 2015). Furthermore, 
vitamin D would have beneficial effects on NAFLD through modulation of adipokines such as 
adiponectin (Abenavoli et al., 2016; Nakano et al., 2011). 
The first cross-sectional study that evaluated the association between vitamin D deficiency and 
NAFLD was the study by Targher et al in 2007 (Targher et al., 2007).They found that low serum 
levels of 25 (OH) D were independently associated with severity of hepatic injuries in NAFLD 
patients(Targher et al., 2007). From that time up to the present, the results of many case-control 
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and cross-sectional studies regarding the association between vitamin D deficiency and NAFLD 
have been published (Barchetta et al., 2011; Nelson et al., 2016; Wang et al., 2016a). 
Furthermore, the results of a recent meta-analysis that systematically evaluated case-control and 
cross-sectional studies, revealed that the risk of vitamin D deficiency in NAFLD patients was 
1.26 times more than healthy controls (OR 1.26, 95% CI: 1.17, 1.35)(Eliades et al., 2013). 
However, the observational studies, especially the cross-sectional ones cannot derive the causal 
relationship between vitamin D deficiency and NAFLD. Meanwhile, whether vitamin D 
deficiency is one of the causes of NAFLD or the result of physiological and metabolic 
disturbances involved in the disease is not yet clear. The best study design that can clarify such 
relationship is clinical trial. If the findings of well-designed clinical trials indicate no effect of 
vitamin D supplementation on NAFLD, it can be concluded that the results of 
previousobservational studies that found the association between vitamin D deficiency and 
NAFLD could probably be due to confounding factors. As a result, in present study, we critically 
and systematically reviewed the clinical trials that evaluated the effects of vitamin D 
supplementation on NAFLD, aiming to develop hypotheses that can integrate findings. 
2. Materials and Methods 
2.1 Search strategy 
A systematic literature search was performed for randomized controlled trials (RCTs), non-
randomized interventions and uncontrolled clinical trials (UCTs), reporting the effects of vitamin 
D supplementation on hepatic steatosis, liver enzymes, and/or insulin sensitivity in adults with 
NAFLD, including non-alcoholic steatohepatitis but no cirrhosis or hepatocellular carcinoma. 
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It was considered sufficient for studies to provide their own diagnostic criteria based on one or 
more of the following: (1) histological examination of biopsies; (2) proton magnetic resonance 
spectroscopy (MRS); (3) computed tomography (CT); (4) ultrasound; and/or (5) blood 
concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). 
The primary outcomes of interest included changes in hepatic steatosis assessed by liver biopsy, 
MRS, CT, or ultrasound, and histologicalindicators of inflammation and fibrosis. Blood ALT 
and/or ASTconcentrations were also considered. The secondary outcomes were glucose 
tolerance and/or insulin sensitivity assesseddirectly by insulin clamp techniques or oral glucose 
tolerancetests, or inferred by validated formulasuch as the homeostasis model assessment of 
insulin resistance (HOMA-IR). The other secondary outcome included inflammatory and 
oxidative stress biomarkers. 
A systematic literature search was performed independently by two authors (RA and NS), from 
inception to April 31- 2017, to identifyand appraise studies of vitamin D supplementation in 
NAFLD. 
The following databases were searched: Medline (Pubmed), Scopus, Cochrane and Google 
Scholar. The selected search terms included: (NAFLD or „„nonalcoholic fatty liver‟‟ or „„non-
alcoholic fatty liver‟‟ or „„nonalcoholic steatohepatitis‟‟ or „„non-alcoholic steatohepatitis‟‟or 
„„nonalcoholic steatosis‟‟ or„„non-alcoholic liver steatosis‟‟ or „„non-alcoholic steatosis‟‟ or 
„„non-alcoholic hepatic steatosis‟‟ or „„nonalcoholic hepatic steatosis‟‟ or „„nonalcoholic liver 
steatosis‟‟) AND (“vitamin D” or “25-hydroxyvitamin D” or “25(OH)D” or “cholecalciferol” or 
“ergocalciferol” or “calcitriol”). 
 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Fl
or
ida
] a
t 0
8:4
7 1
7 O
cto
be
r 2
01
7 
ACCEPTED MANUSCRIPT 
ACCEPTED MANUSCRIPT 7 
2.2 Inclusion and exclusion criteria 
Two researchers also independently determined studies eligible for review. Included studies 
employed trials involving vitamin D supplementation versus placebo, vitamin D supplementation 
and calcium supplementation versus calcium alone and/or placebo.Additional inclusion criteria 
were: (i) the study population consisted of patients with NAFLD and/or NASH; (ii) 
supplementation of vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol) for intervention; 
(iii) Hepatic steatosis (assessed by liver biopsy, MRS, CT, or ultrasound), liver enzymes and 
histologicalindicators of inflammation and fibrosis had to be a primary or secondary outcome; 
(iv) the study performed in subjects≥18 years; (vi) published in English. Studies were excluded if 
they used 1,25-dihydroxyvitamin D and studies performed in patients with alcoholic, drug-
induced, total parenteral nutrition-induced, viral or genetic causes of liver injury. The study types 
such as case-reports, review, commentary or editorial were not included. Bibliographic 
references of searched articles were also examined to look for additional studies. 
 
2.3 Data items 
The items that were considered from each report included: study design; country; sex; age; 
diagnostic criteria for NAFLD/NASH; randomization and blinding; comparability of groups at 
baseline; type and dose of vitamin D supplementation; baseline and changes in serum 25(OH)D; 
definitionof subject adherence; intervention protocol; reported adherence; assessment the dietary 
intakes andphysical activity; assessment of hepatic steatosis; serum ALT and/or AST 
concentrations; measures of glycemia and insulin resistance parameters; inflammatory and 
oxidative stress biomarkers. 
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2.4 Data extraction 
Data extraction from individual studies was performed separately by the authors and any 
differences in data extraction were discussed between them and resolved.Itemized tables were 
used to record relevant data from the reports. To facilitate comparison between studies, results 
were converted to same units and values of changes from baseline converted to percentages.  
 
2.5 Study quality assessment 
The methodological quality of the articleswas assessed by both authors. A modified Downs and 
Black's checklist provided a standardized scale to assess the quality of both randomized and non-
randomized controlled trials (Downs and Black, 1998).This checklist with its items has been 
presented in Supplementary Table 1. This checklist has several categories: reporting, external 
validity, internal validity (bias), internal validity (confounding), and power. Each category 
generated a score; the scores were then summed for a total quality score. In the modified 
checklist, scores greater than or equal to 20 are considered high quality studies, scores between 
15 and 19 and scores of 14 and below are considered fair and poor, respectively.In thepresent 
study, the population for checklist items was defined as participants aged ≥18 diagnosed with 
NAFLD or NASH. Potential confounders (item 5) were age, gender, BMI, season, baseline 
dietary and biochemistry values, change in dietary intake/exercise and medications. For item 27, 
the study power was adjusted to score using a 3-option scale. The scores of 1 or 2 were given if a 
study mentioned conducting power analysis to determine the sample size neededto detect a 
significant difference in effect size for one or more outcome measures, respectively. The score of 
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0 was given if the study did not report power analysis. As a result, the total score of the Downs 
and Black checklist changed from 32 to 29points (Supplementary Table 1: Modified Downs and 
Black Checklist). 
To evaluate the quality of uncontrolled clinical trial (UCT),we used the Quality Assessment Tool 
for Before-After (Pre-Post) Studies with no Control Groupthat consists of 11 „yes/no‟ items. 
Each item receives one point for each affirmative answer (Supplementary Table 2).  
 
3. RESULTS 
A total of 122 articles were identified using the search of databases. Of these articles, 110 were 
excluded after screening the abstract because these papers did not clearly meet the criteria or the 
full texts were not available. The full texts ofthe remaining 12 articles were reviewed, with 6 
publications excluded because they did not meet the inclusion criteria (Figure 1). Six 
articleswere included in the final review(four RCTs and two UCTs studies) with a total of 330 
patients(Barchetta et al., 2016; Foroughi et al., 2014; Kitson et al., 2016; Lorvand Amiri et al., 
2016; Papapostoli et al., 2016; Sharifi et al., 2014).  
The included articles were individually scored for their methodological quality using the two 
aforementionedchecklists. The average score across 4RCTswas 22/29 on the modified Downs 
and Black's checklist(Downs and Black, 1998)(Table 1). The reduced quality across studies 
could be due to inadequate reporting of randomization, blinding, loss to follow-upor controlling 
for confounding variables by statistical analyses. The results of quality assessment for two UCTs 
were presented in Table 2(Kitson et al., 2016; Papapostoli et al., 2016).  
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3.1 Exposure measurements 
The form of serum vitamin D that was measured in all of the included studies was 25(OH)D. The 
method for serum assessment of vitamin D was ELISA, chemiluminescence and colorimetric 
assay. The cut off for deficiency was defined as <20 ng/mL for 25(OH)D, however, only in one 
study the values lower than 15 ng/mL of serum vitamin D was set as inclusion criteria(Lorvand 
Amiri et al., 2016).The prevalence of vitamin D deficiency was 65% (70 out of 108 
participants)among patients with NAFLD that had participated in 2 RCTs in which vitamin D 
deficiency was not among the inclusion criteria of them(Barchetta et al., 2016; Sharifi et al., 
2014). 
Averaging the results of the studies revealed that serum levels of 25(OH) D increased by 125% 
after vitamin D supplementation. The form of the vitamin D that was used in all these studies 
was cholecalciferol (vitamin D3).  
Vitamin D supplementation interval was different between the studies. Participants in two 
studies (Barchetta et al., 2016; Lorvand Amiri et al., 2016) received vitamin D supplements in 
daily basis whereas, in four studies(Foroughi et al., 2014; Kitson et al., 2016; Papapostoli et al., 
2016; Sharifi et al., 2014), supplementation was done at weekly intervals.  
The duration of vitamin D supplementation ranged from 10 to 24 weeks among the reviewed 
studies. Only Lorvand Amiri et al., evaluated the effects of vitamin D supplementation, with and 
without calcium, on biochemical and metabolic parameters in patients with NAFLD (Lorvand 
Amiri et al., 2016). 
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3.2 Outcomes measurements 
3.2.1 Effects of vitamin D on hepatic steatosis and liver enzymes 
All 6 studies had evaluated the effects of vitamin D supplementation on hepatic steatosis in 
patients with NAFLD. The method for assessing the changes in liver fat was ultrasound imaging 
in 3 studies (Foroughi et al., 2014; Lorvand Amiri et al., 2016; Sharifi et al., 2014). In a pilot 
study by Kitson et al., liver biopsy was used to detect histopathological changes in patients with 
NASH who received vitamin D supplementation(Kitson et al., 2016). In one study, transient 
elastography was applied to assess the changes in hepatic steatosis and fibrosis(Papapostoli et al., 
2016). In addition to ultrasound, cytokeratin 18 and transforming growth factor β1 (TGF-β1) 
were evaluated as non-invasive biomarkers of NAFLD by Barchetta et al. and Sharifi et al, 
respectively (Barchetta et al., 2016; Sharifi et al., 2014).Of the six included studies, only in 
Lorvand-Amiri et al. and Papapostoli et al., the grade of hepatic steatosis decreased significantly 
after vitamin D supplementation(Lorvand Amiri et al., 2016; Papapostoli et al., 2016). However, 
the study by Papapostoli et al. was an uncontrolled clinical trial (Papapostoli et al., 2016).  
All six researches measured serum concentrations of liver aminotransferases (ALT and 
AST).Serum levels of ALT and AST significantly decreased after vitamin D supplementation in 
two studies (Lorvand Amiri et al., 2016; Papapostoli et al., 2016) . In Lorvand Amiri et al. study, 
vitamin D supplementation, both alone and in combination with calcium, significantly lowered 
the serum levels of aminotransferases in NAFLD patients with vitamin D deficiency (Lorvand 
Amiri et al., 2016). 
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3.2.2 Effects of vitamin D on insulin resistance, oxidative stress and inflammatory 
biomarkers 
Glucose metabolism parameters were measured in 5 studies, however, only in one study, their 
changes were significant (Lorvand Amiri et al., 2016). Lorvand Amiri et al. found that daily 
supplementation with 1000 IU vitamin D both alone and in combination with calcium could 
significantly decrease HOMA-IR and serum fasting blood glucose (FBG) in patients with 
NAFLD (Lorvand Amiri et al., 2016). Particularly, the decrease was more pronounced in the 
study group that received calcium with vitamin D supplements (Table 3). 
The inflammatory biomarkers that were assessed as secondary outcomes in most studies were 
high-sensitive C-reactive protein (hs-CRP) and tumor necrosis factor α (TNF-α). Among the 3 
studies that measured serum hs-CRP (Barchetta et al., 2016; Foroughi et al., 2014; Sharifi et al., 
2014) , only the results of study by Sharifi et al. showed a near significant decrease in this 
biomarker post- supplementation(Sharifi et al., 2014).  
The oxidative stress biomarkers were measured in one of the six reviewed studies(Sharifi et al., 
2014). The results of Sharifi et al. study revealed that supplementation with vitamin D could 
significantly decrease serum levels of malondialdehyde (MDA), a lipid peroxidation biomarker, 
in patients with NAFLD(Sharifi et al., 2014). However, the change in serum total antioxidant 
capacity was not significant when compared to the control group(Sharifi et al., 2014). 
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3.2.3Effects of vitamin D on adiponectin and pro-fibrotic biomarkers  
The obtained results from three studies, that measured serum levels of adiponectin, did not 
demonstrate any significant changes in this adipokine after vitamin D supplementation 
(Barchetta et al., 2016; Kitson et al., 2015; Sharifi et al., 2014).  Transforming growth factor β1 
(TGF-β1) and procollagen III propeptide were evaluated as biomarkers of liver fibrosis by 
Sharifi et al. and Barchetta et al., respectively (Sharifi et al., 2014; Barchetta et al., 2016). 
However, they did not find significant changes in these biomarkers post-supplementation. 
3.3 Confounding Variables 
Age, sex, body mass index, percent of body fat, dietary intakes, physical activity and seasonal 
variation were determined from the literature as potential confounders of the association between 
vitamin D and NAFLD. Out of the six studies, three adjusted for age and sex (Barchetta et al., 
2016; Lorvand Amiri et al., 2016; Sharifi et al., 2014), five for BMI(Barchetta et al., 2016; 
Foroughi et al., 2014; Kitson et al., 2016; Lorvand Amiri et al., 2016; Sharifi et al., 2014), three 
for percent of body fat(Kitson et al., 2016; Lorvand Amiri et al., 2016; Sharifi et al., 2014), three 
for dietary intakes and two for physical activity(Foroughi et al., 2014; Lorvand Amiri et al., 
2016; Sharifi et al., 2014). Only in two studies the effect of seasonal variation on variable 
changes was examined by comparing data collected in different seasons(Papapostoli et al., 2016; 
Sharifi et al., 2014). Also, Barchetta et al. compared the used medications between cases and 
controls as a confounding variable(Barchetta et al., 2016). Foroughi et al. reported overall data 
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regarding sex and age but did not elaborate on the statistical significance of these data when 
compared the groups at baseline(Foroughi et al., 2014). 
 
4. DISCUSSION 
For the first time, present study reviewed critically and systematically the available clinical trials 
that have evaluated the effects of vitamin D supplementation on hepatic steatosis, liver enzymes, 
insulin resistance and biomarkers of inflammation and oxidative stress in patients with  NAFLD.  
In four studies, vitamin D supplementation did not significantly affect liver steatosis.Only in two 
studies the grade of hepatic steatosis and liver enzymes decreased significantly post-
supplementation(Lorvand Amiri et al., 2016; Papapostoli et al., 2016). Lorvand-Amiri et al. 
conducted a 12-week RCT in 120 NAFLD patients that randomly assigned to receive 1000 IU 
vitamin D3 (n = 37), 500 mg calcium carbonate plus 1000 IU vitamin D3 (n = 37), or placebo (n 
= 36) every day following a weight-loss program. At the end of the study, vitamin D supplement, 
both alone and in combination with calcium, significantly improved the grade offatty liver 
(measured by ultrasound imaging) and serum concentrations of aminotransferases(Lorvand 
Amiri et al., 2016).  The study design of Lorvand-Amiri et al. differs from that of the other 
reviewed trials in some ways (Lorvand Amiri et al., 2016). They included patients with NAFLD 
who had vitamin D deficiency (serum levels < 15 ng/mL) and moderate dietary calcium intake 
(700-800 mg/d)(Lorvand Amiri et al., 2016). Moreover, the participants followed a 500-kcal 
energy deficit diet throughout the intervention. These factors, along with vitamin D 
supplementation, might have an impact on the resultant improvement in the grade of fatty liver. 
Some evidence suggests that the most beneficial effects of a nutrient supplementation occur 
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during the process of restoring its reserves in the body(Heaney, 2008). In other words, giving 
additional amounts of vitamin D to participants who already have sufficient serum levels might 
not produce expected outcomes(Heaney, 2012). The study by Papapostoli et al., that found a 
decrease in the grade of hepatic steatosis after vitamin D supplementation, also included NAFLD 
patients with vitamin D deficiency (Papapostoli et al., 2016). However, low sample size and the 
lack of control group were the limitations of their study. On the other hand, Barchetta et al. 
performed a post-hoc analysis to examine the hypothesis that vitamin D supplementation could 
exert beneficial effects on hepatic steatosis only in patients affected by hypovitaminosis D. 
However, the obtained results did not confirm this hypothesis (Barchetta et al., 2016). 
It should be noted that some of the indirect biological effects of vitamin D are mediated through 
its role in regulating the homeostasis of the calcium ion in the body (Major et al., 2009; Pittas et 
al., 2007). Therefore, the amount of calcium intake might influence the effects of vitamin D on 
metabolic profiles and hepatic steatosis in patients with NAFLD. The dietary intake of calcium 
was reported only in the studies by Lorvand-Amiri et al. and Sharifi et al (Lorvand Amiri et al., 
2016; Sharifi et al., 2014). Because these two clinical trials differed in study design, it is not 
possible to interpret and compare their results based on theparticipants' baseline calcium intake. 
To examine the hypothesis that baseline dietary intake of calcium could influence the effects of 
vitamin D on primary or secondary outcomes in patients with NAFLD, it is needed to design a 
well-powered randomized controlled trial with groups of participants with different levels of 
calcium intake.  
Applying different methods to assess hepatic steatosis and fibrosis could influence the results. 
Four clinical trials in our review used ultrasound to diagnose and measured the degree of 
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steatosis. It should be noted that ultrasound method subjectively measures hepatic steatosis and 
could not detect any liver histological changes as precisely as detected by liver biopsy(Saleh and 
Abu-Rashed, 2007). Liver biopsy remains the gold standard. However, its use is restricted in 
population-based studies and large clinical trials as a result of cost and ethical issues(Saleh and 
Abu-Rashed, 2007). Only Kitson et al. applied liver biopsy to evaluate the impact of high-dose 
oral vitamin D3 supplement (25 000 IU/week) over 24 weeks on liver histology and metabolic 
profile in 12 non-cirrhotic patients with NASH(Kitson et al., 2016). Their findings showed no 
impact of vitamin D supplementation on NAFLD activity score and liver biochemistry, insulin 
resistance or adipocytokine profile (Kitson et al., 2016). Low sample size and lacking control 
group were among the limitations of their study. 
Among the newer non-invasive imaging methods, magnetic resonance spectroscopy (MRS) is an 
accurate and quantitative method for NAFLD diagnosis(Cobbold et al., 2012). None of the 
included studies used MRS as a method of monitoring the changes in liver steatosis. Transient 
elastography (Fibroscan) has also recently applied for detecting and quantifying steatosis, by 
using an index named Controlled Attenuation Parameter (CAP)(de Ledinghen et al., 2010). This 
technique is able to detect and quantify the hepatic steatosis even when the level of accumulated 
fat is as low as 10% (Dowman et al., 2011). In this review, Papapostoli et al. used transient 
elastography to measure hepatic steatosis (Papapostoli et al., 2016). They included 40 patients 
with significant liver fat accumulation (CAP value ≥ 280 dB/m). The patients received 20,000 IU 
vitamin D/week for six months. At the end of study, restoration of serum vitamin D levels was 
accompanied by significant reduction in CAP values relative to baseline(Papapostoli et al., 
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2016). However, as the author indicated, the lack of control group was the main limitation of 
their study. 
Measuring the non-invasive serum biomarkers of NAFLD along with imaging techniques can 
help increase the quality and accuracy of the study results (Dowman et al., 2011; Fitzpatrick and 
Dhawan, 2014). Barchetta et al. conducted a double-blind, placebo-controlled trial to assess the 
beneficial effects of oral vitamin D3 (2000 IU/day) or placebo for six months in type 2 diabetic 
patients with NAFLD(Barchetta et al., 2016). To measure the changes in severity of NAFLD, 
they considered serum levels of cytokeratin 18 M-30 (marker of hepatocytes 
apoptosis)(Fitzpatrick and Dhawan, 2014), procollagen III propeptide (marker of liver fibrosis), 
transaminases and fatty liver index (FLI) as primary outcomes in addition to the monitoring the 
hepatic steatosis by magnetic resonance imaging (MRI). They concluded that oral vitamin D 
supplementation over 24 weeks did not improve hepatic steatosis and metabolic parameters in 
type 2 diabetic patients with NAFLD. Of note, this clinical trial has received one of the highest 
scores regarding methodological quality in present systematic review. 
Insulin resistance (IR) is one of the important key factors in development and progress of 
NAFLD(Dowman et al., 2010). Most of the included studies did not demonstrate any significant 
changes in IR or other glucose metabolism parameters after vitamin D supplementation in 
NAFLD patients. However, only in one research, daily supplementation with 1000 IU vitamin D 
for 12 weeks, both alone and in combination with calcium, could significantly decrease HOMA-
IR and fasting serum glucose in patients with NAFLD(Lorvand Amiri et al., 2016).Additionally, 
the decrease was more pronounced in the study group that received calcium in addition to 
vitamin D supplements(Lorvand Amiri et al., 2016). This finding might confirm the proposed 
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mechanism that vitamin D could improve insulin secretion and action indirectly via regulating 
extracellular calcium and calcium flux(Pittas et al., 2007). In other words, co-supplementation of 
vitamin D and calcium may have synergistic effects on insulin secretion and action. On the other 
hand, to better elucidate the effect of vitamin D on insulin resistance. Barchetta et al. included 
NAFLD patients with type 2 diabetes (Barchetta et al., 2016). Although they used a higher dose 
of vitamin D supplement and longer duration of intervention than those of the clinical trial by 
Lorvand-Amiri et al., they did not find any significant changes in insulin resistance or sensitivity 
indices(Barchetta et al., 2016; Lorvand Amiri et al., 2016). Previous studies also reported 
conflicting results regarding the effects of vitamin D on insulin resistance in other chronic 
diseases(Pittas and Dawson-Hughes, 2010). Duration of vitamin D supplementation, measuring 
methods of IR and vitamin D receptor (VDR) gene polymorphisms are among the potential 
reasons for finding conflicting results regarding the effect of vitamin D on IR(Pittas and 
Dawson-Hughes, 2010). None of the included trials in our review had used more valid and 
accurate methods such as euglycemic clamp technique or intravenous glucose tolerance test to 
assess IR and glucose metabolism. However, application of these methods for epidemiologic 
studies and clinical trials are not feasible because they are time-consuming, labor-intensive, 
expensive, and requires an experienced operator to manage technical difficulties(Hannon et al., 
2017).Several polymorphisms of the VDR gene have been identified, namely BsmI, ApaI, TaqI, 
and FokI (Alexandra et al., 2013). In some population, TaqI and FokI polymorphisms were 
related to type2 diabetes and insulin resistance(Nosratabadi et al., 2015). Interestingly, some 
genotype of VDR polymorphism were slow to respond to vitamin D intake in terms of 
circulating 25(OH)D, IR and inflammatory markers(Shab-Bidar et al., 2011). Therefore the 
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longer intervention duration is needed to find an expected effect of vitamin D supplementation 
on some metabolic profile such as IR in populations who have specific VDR gene 
polymorphisms. 
Inflammation and oxidative stress play important roles in the progression from simple steatosis 
to more advanced form of NAFLD(Jou et al., 2008). Of the trials, only in one, that was published 
by our research group, supplementation with vitamin D (50000 IU/bi-weekly) for 16 weeks led 
to near the significantdecline in serum levels of hs-CRP (a biomarker of inflammation) and 
decreased serum MDA (a biomarker of lipid peroxidation) significantly in adults patients with 
NAFLD (Sharifi et al., 2014). The other two studies that used serum biomarkers of inflammation 
as secondary outcomes, did not find any beneficial effects of vitamin D supplementation on these 
biomarkers(Barchetta et al., 2016; Foroughi et al., 2014). Such inconsistency also exists between 
the results of previous studies that assessed the effects of vitamin D on systemic inflammation 
among patients with other chronic diseases that might be due to differences in diseases, subjects, 
type and doses of vitamin D supplementation and follow-up duration (Beilfuss et al., 2012; 
Zittermann et al., 2009). 
Fibrosis is the advanced form of NAFLD that predisposes patients to liver cirrhosis (Cheah et al., 
2017). The activation of hepatic stellate cells (HSC), during chronic liver injury, is responsible 
for liver fibrosis(Consolo et al., 2009). In addition to collagen production, HSC also secrete the 
inhibitors of metalloproteinase enzyme, thereby preventing the degradation of extracellular 
matrix proteins (Consolo et al., 2009). These cells also secrete transforming growth factor β1 
(TGF-β1), which contributes to the activation of other adjacent HSC from the paracrine 
pathways (Breitkopf et al., 2006). It has been proposed that vitamin D can decrease TGF-β1 
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production via both VDR and non-VDR pathways, and may reduce the progression of liver 
fibrogenesis, especially in the early stages of NAFLD (Beilfuss et al., 2014). In present 
systematic review, Barchetta et al. And Sharifi et al., 2014 evaluated the effects of vitamin D 
supplementation on serum fibrosis biomarkers such as TGF-β1 and procollagen III propeptide. 
However, they did not find significant changes in these serum biomarkers post supplementation 
(Barchetta et al., 2016; Sharifi et al., 2014).Further studies will reveal more facts in this area 
Recently, the interactions between the liver and the gut have been investigated as one of the 
underlying causes of NAFLD onset and progression (Abenavoli et al., 2016; Eliades and Spyrou, 
2015).  Increased intestinal permeabilityleads to the translocation of bacterial products from 
lumen to the portal circulation(Poeta et al., 2017). Bacterial products such as lipopolysaccharides 
(LPS) trigger liver inflammation and inducing the innate immune response (Cani et al., 2008). 
Toll Like receptor-4 (TLR-4) is activated in response to bacterial LPS exposure (Miura and 
Ohnishi, 2014). Evidence revealed a significant association between TLR-4 activation and 
NAFLD (Miura and Ohnishi, 2014). Since VDR is widely expressed in non-parenchymal liver 
cells like macrophages and Kuppfer cells, it seems that vitamin D can modulate innate immunity 
via VDR signalling in these types of hepatic cells (Zúñiga et al., 2011).  However, there are no 
randomized controlled trials studying whether vitamin D replacement is beneficial in modulating 
the immunity responses that are arisen from the gut-liver axis. This can be a potential research 
topic for future studies. 
Some previous cross-sectional studies reported a significant association between serum levels of 
vitamin D and NAFLD only in men (Park et al., 2017; Zhai et al., 2016). Gender differences 
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have been proposed as a factor that might affect the relationships between serum vitamin D and 
NAFLD (Wang et al., 2016b). The mechanisms for such interaction have not been completely 
understood. Some reports referred the mechanisms to the existence of differences in sex 
hormones related factors between the genders (Wang et al., 2016b). We previously conducted a 
post hoc subgroup analysis within our clinical trial in NAFLD patients to determinethe effects of 
vitamin D on hepatic steatosis and other metabolic profiles separately in men and women 
(Sharifi et al., 2016). Our results indicated that improved vitamin D status might decrease serum 
total cholesterol (TC) and low density lipoprotein-cholesterol (LDL-C) levels as well as hs-CRP 
in women with NAFLD. However, it might increase serum TC in men(Sharifi et al., 2016). The 
other clinical trials reviewed here did not perform subgroup analysis to evaluate the gender 
differences. 
Various doses and durations of vitamin D supplementation have been used by reviewed clinical 
trials in patients with NAFLD. Moreover, controversies exist in the obtained results from limited 
number of studies. As a result, it seems premature to recommend vitamin D supplementation for 
the specific treatment of NAFLD based on current limited data. Further randomized, placebo-
controlled trials are needed to better determine the appropriate doses and the efficacy of vitamin 
D supplementation in patients with NAFLD. Until then, it is recommended to follow The 
Endocrine Society’s Clinical Guidelines in The Treatment and Prevention of Vitamin D 
Deficiency, in order to correct serum vitamin D levels in patients with NAFLD suffering from 
vitamin D deficiency (Holick et al., 2011). 
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Most recently, a systematic review and meta-analysis study has been published that, aimed to 
investigate clinical trials related to the effects of vitamin D on NAFLD (Tabrizi et al., 2017). 
However, our study has some strengths that distinguish it from the meta-analysis study by 
Tabrizi et al (Tabrizi et al., 2017).We applied extensive literature search and strict adherence to 
PRISMA guidelines to identify all the relevant articles(Liberati et al., 2009). When evaluating 
studies in order to enter them into our systematic review, we found several papers from the same 
research group that reported data from the same group of patients. Therefore, in order to prevent 
possible errors, we considered the similar published papers derived from the same research group 
as a single study and did not include them as separate ones in our systematic review. Moreover, 
we included clinical trials from different countries while all trials in meta-analysis by Tabrizi et 
al were from a same country that could restrict generalizability of their results. Additionally, to 
explore the methodological quality of the included studies, we applied Downs and Black 
checklist not only for the quality of reporting, internal validity (bias and confounding) and 
power, but also for external validity (Downs and Black, 1998). Due to the limited number of 
clinical trials published on vitamin D and NAFLD, it was anticipated that the heterogeneity 
would be high among them. Therefore, we did not perform meta-analysis, because the meta-
analysis findings are not conclusive when considerable heterogeneity exists among the included 
studies (Higgins et al., 2003). Indeed, one of the important goals of the present study was to 
critically discuss and compare the design and findings of clinical trials in order to provide 
hypotheses and suggestions that help design future studies to better elucidate the therapatic role 
of vitamin D in NAFLD. 
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4.1 Future direction 
Based on the results from of clinical trials in the present study, it seems that additional questions 
remain to be addressed in future studies regarding the effects of vitamin D supplementation on 
NAFLD. In order to avoid repeating studies with similar design we would suggest the following 
points: 
 If possible, more accurate measurement methods for monitoring the primary (e.g. liver 
biopsy, MRS or Fibroscan) or secondary outcomes (e.g. euglycemic clamp technique for 
IR) should be applied. 
 It would be better to compare the effects of vitamin D supplementation on NAFLD 
outcomes between study groups with different subtypes of steatosis, NASH and liver 
fibrosis. 
 At least one of the non-invasive biomarkers of NAFLD should be measured to increase 
the quality and accuracy of the study results  
 Study with the specific objective to compare the effects of vitamin D supplementation on 
NAFLD between subjects with vitamin D deficiency and those with sufficient vitamin D 
would be more inclusive. 
 Study with the specific objective to compare the effects of vitamin D supplementation on 
NAFLD between the study groups with different levels of dietary calcium intake is 
suggested. 
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 Conducting a single large randomized controlled trial that simultaneously evaluates the 
effects of vitamin D and calcium supplementation, alone or in combination, on NAFLD 
parameters would bring advanced results.  
 Considering the effects of gender differences on relationship between vitamin D 
supplementation and outcomes of NAFLD can illustrate more specific therapeutic 
approach. 
 Evaluating the effects of vitamin D supplementation on serum biomarkers of 
inflammation and oxidative stress along with other outcomes of NAFLD is suggested. 
 Investigating the effects of VDR gene polymorphism on association between vitamin D 
supplementation and NAFLD is a new field to assess. 
4.2 Conclusion 
The results obtained from this review, provide new insight into the factors that could affect the 
therapeutic role of vitamin D in NAFLD. Factors such as gender differences, baseline serum 
status of vitamin D, baseline dietary intake of calcium, gene polymorphism, different subtypes of 
NAFLD, co-supplementation with calcium, as well as using accurate outcome measurement 
methods and longer period of intervention should be considered when designing future 
randomized clinical trials in this field.     
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Table 1: Quality scores of the included RCTs assessed by Downs and Black checklist. 
Total quality 
score 
<14 = poor 
15–19 = fair 
>20 = good 
Power 
 
 
Total score:3 
Internal 
validity-
confounding 
Total score:6 
Internal 
validity-
biased 
Total score:7 
External 
validity 
 
Total score:3 
Reporting 
 
 
Total score:10 
Author, 
year 
22/29 1 5 5 2 9 Lorvand 
Amiri et 
al., 2016 
25/29 1 5 7 2 10 Barchetta 
et al., 2016 
18/29 1 3 6 1 7 Foroughi 
et al., 2014 
24/29 1 6 7 1 9 Sharifi et 
al., 2014 
  RCTs, Randomized controlled trial 
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Table 2:Quality scores of the included UCTs assessed by Quality Assessment Tool for Before-
After (Pre-Post) Studies With No Control Group* 
 
Author, 
year 
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Total 
Score 
Papapostoli 
et al., 2016 
 
Y Y N Y CD Y Y NR Y Y Y 8/11 
Kitson et 
al., 2016 
Y N Y N N Y Y NR NA Y N 5/11 
* Each question receives one point for each affirmative answer. For more detail about each question please refer 
to Supplementary Table 2. 
CD, can not determine; NR, not reported; N, no; Q, question; UCT, uncontrolled trial; Y,yes 
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 Table 3:Studies that evaluated the effect of vitamin D supplementation on NAFLD outcomes 
Author, 
year, 
 
Count
ry 
Desig
n 
Total 
Sample 
size 
(M/F) 
Study 
Populatio
n 
Age 
years 
BMI 
(kg/m2) 
Interventio
n and study 
groups 
Duration  
(wks) 
Serum vitamin 
D levels 
(ng/mL) Before 
(BI) and After 
intervention(AI) 
Outcomes Results 
 
Lorvan
dAmiri 
et al., 
2016 
 
Iran 
 
RCT 
 
110 
(68/42) 
 
 
 
NAFLD 
with VDD 
 
39.8±11 
 
30.3±0.6
4 
 
G 1: 
Vitamin D3 
(1000 
IU/d)+ 
placebo+ 
weight loss 
diet 
 
G2 : 
Vitamin 
D3+calcium 
carbonate 
(1000 IU/d + 
500 
mg/d)+weig
ht loss diet 
 
G 3: 
Placebo+wei
ght loss diet 
 
 
12 
 
BI 
G1: 9.9±0.64 
G2: 9.9±0.64 
G3: 10± 0.63 
 
AI 
G1:21.4±0.73 
G2: 27.1±1.1 
G3: 11± 0.87 
 
 
HS 
(Ultrasoun
d), 
ALT,AST
,FBG,HO
MA-IR, 
BMI 
 
Relative to 
baseline: 
Group 1: 
HS ↓ in 89% 
of subject,  
Vitamin D 
↑116%  
ALT ↓7%, 
AST↓14%, 
HOMA-IR 
↓19%, 
FPG↓2% , 
BMI↓3% 
 
Group 2: 
HS ↓ in 73% 
of subject,  
Vitamin D 
↑174%  
ALT ↓28%, 
AST↓17%, 
HOMA-IR 
↓31%, 
FPG↓9%, 
BMI↓4% 
 
Group 3: 
HS ↓ in 11% 
of subject, 
BMI↓4%,  
ALT, AST, 
HOMA-IR, 
FPG : n/s 
 
 
Barchet
ta et al., 
2016 
 
 
Italy 
 
 
RCT 
 
 
55 
(35/20) 
 
 
 
 
 
NAFLD 
subjects 
with 
Type2 
diabetes 
 
 
58.7±9.
9 
 
 
29.3±4.4 
 
 
Vitamin 
D3(2000 
IU/d) 
 
Placebo 
 
 
24 
 
 
BI: 17.24 
AI: 34.32 
 
 
 
HS 
(Ultrasoun
d & MRI), 
FLI, 
ALT,AST
, CK-
M30, γ-
GT, 
FBG,HO
MA-IR, 
hs-CRP, 
Adiponect
in 
 
Relative to 
baseline: 
 
Vitamin D 
↑100%  
No 
significant 
changes in 
any of the 
outcomes' 
measures 
 
Papapo
stoli,et 
 
Germa
ny 
 
 
UCT 
 
 
40 
 
Patient 
with 
 
 
54.9±12
 
 
29.5±3.0 
 
 
Vitamin D3 
 
 
24 
 
 
BI: 11.8±4.8 
 
HS 
(Transient 
 
Relative to 
baseline: 
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al. 2016 (21/19) hepatic 
steatosis 
and VDD 
 
 
.1 (20,000 
IU/week) 
AI: 34.8±9.8 
 
elastograp
hy),ALT,
AST, 
ALP, γ-
GT, fat-
mass, Ca, 
PTH 
 
HS ↓ 7% , 
Vitamin D 
↑195%  
PTH↓ 26% 
 
ALT,AST, 
ALP, γ-GT, 
fat-mass, Ca: 
n/s 
 
 
Kitson 
et al., 
2015 
 
 
Austra
lia 
 
 
UCT 
(pilot 
study) 
 
 
12 (n/r) 
 
 
Non-
cirrhotic 
patients 
with 
biopsy 
proven 
NASH 
 
 
n/r 
 
 
n/r 
 
 
Vitamin D3 
(25.000 
IU/week) 
 
 
24 
 
 
BI: 25.2±12.6 
AI: 43.9 ±6.24 
 
NAFLD 
activity 
score, 
ALT,AST
, γ-GT, 
HbA1c, 
HOMA-
IR, 
Adiponect
in 
 
 
Relative to 
baseline: 
 
Vitamin D 
↑74%  
 
No 
significant 
changes in 
values of 
other 
outcomes 
 
 
Foroug
hi, et 
al., 
2014 
 
 
Iran 
 
 
RCT 
 
 
60 
(29/31) 
 
 
Patients 
with 
NAFLD 
 
 
48.5 
 
 
31.2±4 
 
 
Vitamin D3 
(50,000 
IU/week) 
 
Placebo 
 
 
10 
 
 
BI: 19.6±1 
AI: 46.8±13 
 
HS 
(Ultrasoun
d), 
ALT,AST
, hs-CRP, 
Ca 
 
Relative to 
baseline: 
 
Vitamin D 
↑138% , Ca 
↑37% 
 
HS,ALT,AS
T, hs-CRP: 
n/s 
 
 
Sharifi, 
et al., 
2014 
 
 
Iran 
 
 
RCT 
 
 
53 
(26/27) 
 
 
Patients 
with 
NAFLD 
 
 
42.1±9.
2 
 
 
30.8±4.6 
 
Vitamin D3 
(50,000 
IU/bi 
weekly)+ 
Recommend
ation for 
lifestyle 
modification 
 
Placebo+ 
Recommend
ation for 
lifestyle 
modification 
 
 
 
 
16 
 
 
BI: 16.4±9.7 
AI: 37.4 ±16.3 
 
HS 
(Ultrasoun
d), 
ALT,AST
, 
ALP,FBG
, HOMA-
IR,hs-
CRP, 
TNF-α, 
TGF β1, 
MDA, 
Adiponect
in 
 
Relative to 
baseline: 
 
Vitamin D 
↑128%  
hs-CRP 
↓13% , 
MDA ↓ 
51%,  
 
 
No 
significant 
changes in 
values of 
other 
outcomes 
 
 
Data are mean ± standard errors usually rounded to the nearest full figure; Sample size reflects those in the final analysis. 
AI, after intervention; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase ;BI, before intervention; BMI, body 
max index (kg/m2); Ca, calcium; CK-M30, cytokeratin 18; d, day(s); F, female; FBG, fasting blood glucose; FLI, fatty liver index; G1, group1; G2, 
group 2; G3, group 3; HbA1c, glycated haemoglobin; HOMA-IR, homeostasis model assessment; HS,hepatic steatosis; hs-CRP, high-sensitive C 
reactive protein; M, male; MDA, malondialdehyde; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; n/r, data not 
reported; n.s., result not statistically significant; PTH, parathyroid hormone; RCT, randomised controlled trial; TGF β1, transforming factor β1; TNF-α, 
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tumor necrosis factor -α ; UCT, uncontrolled trial; γ-GT, gamma glutamyltransferase 
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Figure 1. 
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